Does Lutetium Lu 177 Dotatate Interact with Somatostatin?
CDI records a major classification for Lutetium Lu 177 Dotatate and Somatostatin. The stored summary is: Somatostatin analogs competitively bind to somatostatin receptors and may interfere with LUTATHERA efficacy. Discontinue long-acting analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each dose. The mechanism involves competitive binding to somatostatin receptors. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Competitive binding to somatostatin receptors
What To Tell Your Doctor or Pharmacist
If you are taking Lutetium Lu 177 Dotatate and your doctor is considering prescribing Somatostatin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider